Methotrexate: what to check before you give it

Why this drug and not another

Low-dose methotrexate is a mainstay disease-modifying antirheumatic drug because it suppresses the immune-mediated inflammation driving conditions like rheumatoid arthritis and psoriasis, slowing joint damage rather than just masking pain. This is an entirely different dosing philosophy and risk profile from the high-dose methotrexate used in oncology, where it is given under strict protocols with leucovorin rescue.

It is chosen over biologics as a first-line option partly on cost and long track record, and it is frequently combined with a biologic later rather than replaced by one. Its narrow margin between therapeutic and toxic dosing is the trade-off for that effectiveness.

Administration and timing

The defining safety point with low-dose methotrexate is that it is given once a week, on the same day each week, never daily. Daily dosing is a documented and fatal medication error, because it delivers a cumulative toxic dose within days rather than the intended weekly exposure.

Folic acid is prescribed on the days methotrexate is not taken, typically the other six days of the week, to reduce gastrointestinal and hepatic side effects without blunting the drug's therapeutic effect. Confirm the patient understands this pattern before discharge, since confusing folic acid's schedule with methotrexate's is a common source of error.

Alcohol is avoided entirely during methotrexate therapy because both substances are hepatotoxic and the combination substantially raises the risk of liver damage over time.

Monitoring parameters

Baseline and periodic full blood count, liver function tests, and renal function are standard, since methotrexate suppresses bone marrow, can cause hepatotoxicity, and is renally cleared. Frequency of monitoring typically increases after a dose change and then settles into a routine interval once the patient is stable, per prescriber and institutional protocol.

A chest X-ray at baseline is common practice given the risk of methotrexate-induced pulmonary toxicity, and any new cough or breathlessness during therapy warrants prompt reporting. Pregnancy status is checked before starting therapy in anyone of childbearing potential, since methotrexate is teratogenic.

Adverse effects to report

Mouth sores, unusual bruising or bleeding, and persistent sore throat or fever all point toward bone marrow suppression and should be reported before the next dose. Yellowing of the skin or eyes, dark urine, or right upper quadrant pain suggest hepatotoxicity and need prompt evaluation.

A new or worsening cough, shortness of breath, or fever can indicate methotrexate-induced pneumonitis, a serious pulmonary reaction that is not dose-related and can occur even at low weekly doses. Severe or unusual gastrointestinal upset beyond mild nausea is also worth reporting, particularly if it is not resolving with the folic acid regimen already in place.

Contraindications and cautions

Pregnancy is an absolute contraindication because methotrexate is teratogenic and used medically to terminate pregnancy at higher doses; reliable contraception is required for patients of childbearing potential during and for a period after therapy, per current prescribing guidance. Breastfeeding is also avoided.

Significant hepatic impairment, heavy alcohol use, and significant renal impairment are cautions or contraindications given the drug's hepatotoxic and renally-cleared profile. Active infection is approached cautiously because of methotrexate's immunosuppressive effect, and live vaccines are generally avoided during therapy.

Teaching points the exam tests

The single most tested fact about methotrexate is the weekly, not daily, dosing schedule, and NCLEX questions frequently present a scenario where a patient has mistakenly taken it daily, expecting you to recognise the error and escalate immediately. This error has caused real fatalities, which is why it appears so consistently.

Expect questions on the folic acid pairing, testing whether you understand it is given on non-methotrexate days to offset side effects without reducing efficacy. Pregnancy prevention counselling and the instruction to avoid alcohol are also standard exam content, alongside recognising early signs of hepatotoxicity or bone marrow suppression in a scenario question.